Chemoprevention strategies for patients with lung cancer in the context of screening

Clinical Lung Cancer

Volumn 7, Issue 2, 2005, Pages 92-99

  Saba, Nabil F ^a,b   Khuri, Fadlo R ^a  

^a EMORY UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Bronchial dysplasia; Carotenoids; Low dose computed tomography; Retinoids

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALITRETINOIN; ALPHA TOCOPHEROL; ANETHOLE TRITHIONE; BETA CAROTENE; CAROTENOID; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FENRETINIDE; GEFITINIB; ISOTRETINOIN; PLACEBO; PLATINUM; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RETINOID; RETINOL; RETINOL PALMITATE; SELENIUM; TIPIFARNIB;

CANCER MORTALITY; CANCER PATIENT; CANCER SCREENING; CANCER SURVIVAL; CANCER THERAPY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DRUG BLOOD LEVEL; DRUG TARGETING; EARLY DIAGNOSIS; HIGH RISK PATIENT; HUMAN; LUNG CANCER; PRECANCER; REVIEW; SMOKING CESSATION;

EID: 32044433314     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2005.n.023     Document Type: Review

References (79)

1. Jemal A, Murray T, Ward E, et al. Cancer Statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
2. Auerbach O, Gere JB, Foreman JB. Changes in the bronchial epithelium in relation to smoking and cancer of the lung. N Engl J Med 1957; 256:98-104.
3. Franklin WA, Veve R, Hursch FR, et al. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 2002; 29:3-14.
4. Zhang LF, Gao WM, Gealy R, et al. Comparison of K-ras gene mutations in tumor and sputum DNA of patients with lung cancer. Biomarkers 2003; 8:156-161.
5. Khuri FR. Primary and secondary prevention of non-small cell lung cancer: the SPORE Trials of Lung Cancer Prevention. Clin Lung Cancer 2003; 5(suppl 1):S36-S40.
6. Soria JC, Kim ES, Fayette J, et al. Chemoprevention of lung cancer. Lancet Oncol 2003; 4:659-669.
7. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal tumor development. N Engl J Med 1988; 319:525-535.
8. Westra WH, Slebos RJ, Offerhaus GJ, et al. K-ras oncogene activation in lung adenocarcinomas from former smokers: evidence that Kras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. Cancer 1993; 72:432-438.
9. Morkve O, Halvorsen OJ, Stangeland I, et al. Quantitation of biological markers (p53, c-myc, Ki-67, and DNA ploidy) by multiparameter flow cytometry in non-small cell lung cancer. Int J Cancer 1992; 52:851-855.
10. Omenn GS, Goodman GE, Thornquist M, et al. Effects of combination of beta-carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334:1150-1155.
11. Henneckens CH, Buring JE, Manson JE. Lack of long-term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334:1145-1149.
12. Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 2001; 93:605-618.
13. Karp DD, Tsao AS, Kim ES. Nonsmall-cell lung cancer: chemoprevention studies. Semin Thorac Cardiovasc Surg 2003; 15:404-420.
14. Van Zandwijk N, Dalesio O, Pasotino U, et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer. Head and Neck and Lung Cooperative groups. J Natl Cancer Inst 2000; 93:605-618.
15. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994; 330:1029-1035.
16. Gudas LJ, Hu L. The regulation and gene expression by retinoids in normal and tumorigenic epithelial cells. Proc Am Assoc Cancer Res 1993; 34:588-589.
17. Hong WK, Lippman JM, Itris L. Prevention of second primary tumors with serotonin in squamous cell carcinoma of the head and neck. N Engl J Med 1990; 334:1145-1149.
18. Pastorino U, Infante I, Maioli M, et al. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 1993; 11:1216-1222.
19. Van Zandwijk N, Dalesio O, Pastorino U, et al. EUROSCAN, a randomized trial of chemoprevention with vitamin A, and N-acetylcysteine in patients with head and neck cancer or lung cancer. J Natl Cancer Inst 2000; 92:977-986.
20. Lam S, MacAulay C, Le Riche JC. A randomized phase IIB trial of anethole dithiolethione in amokers with bronchial dysplasia. J Natl Cancer Inst 2002; 94:1001-1009.
21. Kurie JM, Lotan R, Lee JJ. Treatment of former smokers with 9-cis retinoic acid reverses loss of retinoic acid receptor beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst 2003; 95:206-214.
22. Arnold AM, Browman GP, Levine MN. The effect of synthetic retinoid etretinate on sputum cytology: results from a randomized trial. Br J Cancer 1992; 65:737-743.
23. Lee JS, Lippman SM, Benner SE, et al. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol 1994; 12:937-945.
24. McLarry JW, Holiday DB, Girard WM. Beta-carotene, vitamin A, and lung cancer chemoprevention: results of an intermediate endpoint study. Am J Clin Nutr 1995; 62(6 suppl):1431S-1438S.
25. Kurie JM, Lee JS, Khurie FR. N-(4 hydroxyphenyl) retinamide in the chemoprevention of squamous cell metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res 2000; 6:2973-2979.
26. Lam S, MacAulay C, Le Riche JC, et al. A randomized phase IIB trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst 2002; 94:1001-1009.
27. Eberhart CE, Coffey RJ, Radhika A. Up-regulation of cyclo-oxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107:1183-1188.
28. Herschman HR, Xie W. Up-regulation of cyclo-oxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1995; 107:1183-1188.
29. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983; 24:83-87.
30. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and the reduced incidence of fatal colon cancer. N Engl J Med 1991; 325:1593-1596.
31. Steinbach G, Lynch PM, Phillips RK. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial polyposis. N Engl J Med 2000; 342:1946-1952.
32. Tsoubouchi Y, Mukai S, Kawahito Y. Meloxicam inhibits the growth of non-small cell lung cancer. Research 2000; 20:2867-2872.
33. Masferrer JL, Leahy KM, Koki AT. Antiangiogenic and anti-tumor activities of cyclo-oxygenase-2 inhibitors. Cancer Res 2000; 60:1306-1311.
34. Liao Z, Komaki R, Mason KA, et al. Role of cyclooxygenase-2 inhibitors in combination with radiation therapy in lung cancer. Clin Lung Cancer 2003; 4:56-65.
35. Pyo H, Choy H, Amorino GP. A selective cyclo-oxygenase-2 inhibitor, NS-398, enhances the effect of radiation in-vitro and in-vivo preferentially on the cells that express cyclo-oxygenase-2. Clin Cancer Res 2001; 7:2998-3005.
36. Kim HS, Ypum HR, Lee JS. Correlation between cyclo-oxygenase-2 and tumor angiogenesis in non-small cell lung cancer. Lung Cancer 2003; 42:163-170.
37. Kris MG, Natale RB, Herbst RS. A phase II trial of ZD 1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 2002; 21:292a (Abstract #1166).
38. Giaccone G, Johnson DH, Manegold C, et al. A phase III clinical trial of ZD1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy naive patients with advanced non-small cell lung cancer (INTACT1). Ann Oncol 2002; 13(suppl 5):2 (Abstract #40).
39. Johnson D, Herbst R, Giaccone G, et al. ZD 1839 (Iressa) in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer: results from a phase II trial (INTACT2). Ann Oncol 2002; 13(suppl 5):127 (Abstract #4080).
40. Bollag G, McCormick F. Regulators and effectors of Ras proteins. Annu Rev Cell Biol 1991; 7:601-632.
41. Rosell R, Li S, Skacel Z. prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene 1993; 8:2407-2412.
42. Wistuba II, Lam S, Behrens C, et al. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 1997; 89:1366-1373.
43. Mao L, Lee JS, Kurie JM, et al. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 1997; 89:857-862.
44. Tockman MS, Zhukiv T, Erozan YS, et al. Antigen retrieval improves hnRNP A2/B1 immunohistochemical localization in premalignant lesions of the lung. In: Martinet Y, Hirsch ER, Martinet N, et al, eds. Clinical and Biological Basis of Lung Cancer Prevention. Basel, Switzerland: Birkhauser; 1998:239-246.
45. Tockman MS, Mulshine JL, Piantadosi S, et al. Prospective detection of clinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. Clin Cancer Res 1997; 3:2237-2246.
46. Mills NE, Fishman CL, Scholes J, et al. Detection of K-ras oncogene mutations in bronchoalveolar lavage fluid for lung cancer diagnosis. J Natl Cancer Inst 1995; 87:1056-1060.
47. Adrendt SA, Chow JT, Xu LH, et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 1999; 91:332-339.
48. Palmisano WA, Divine KK, Saccomanno G, et al. predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000; 60:5954-5958.
49. Franklin WA, Gazdar AF, Haney J, et al. Widely dispersed p532 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis [published erratum in J Clin Invest 1997; 100:2639]. J Clin Invest 1997; 100:2133-2137.
50. Yakubovskaya MS, Spiegelman V, Luo FC, et al. High frequency of K-ras mutations in normal appearing lung tissues and sputum of patients with lung cancer. Int J Cancer 1995; 63:810-814.
51. Mao L, Hruban RH, Boyle JO. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 1994; 54:1634-1637.
52. Phillips M, Gleeson K, Hughes JMB, et al. Volatile organic compounds in breath as markers of lung cancer: a cross sectional study. Lancet 1999; 353:1930-1933.
53. 1989 survey of physicians' attitudes and practices in early cancer detection. CA Cancer J Clin 1990; 40:77-101.
54. Lee TH, Brenan TA. Direct-to-consumer marketing for high-technology screening tests. N Engl J Med 2002; 346:529-531.
55. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999; 354:99-105.
56. Henschke CI, Yankelevitz DF, Libby DM, et al. Early lung cancer action project: annual screening using single-slice helical CT. Ann N Y Acad Sci 2001; 952:124-134.
57. Spiral CT screens raise scientific, economic issues. Oncol News Int 2000; 9:1-30.
58. Brett GZ. The value of lung cancer detection by six-monthly chest radiographs. Thorax 1868; 23:414-420.
59. Martini N. Results of the Memorial Sloan-Kettering study in screening for early lung cancer. Chest 1986; 89(4 suppl):325S.
60. Tockman M. Survival and mortality from lung cancerin a screened population: the Johns Hopkins study. Chest 1986; 89(suppl):325S-326S.
61. Fontana RS, Sanderson DR, Woolner LB, et al. Lung cancer screening: the Mayo program. J Occup Med 1986; 28:746-750.
62. Wilde J. A 10-year follow-up of semi-annual screening for early detection of lung cancer in the Erfurt County, GDR. Eur Respir J 1989; 2:656-662.
63. Brett GZ. Early diagnosis and survival in lung cancer. Br Med J 1969; 4:260-262.
64. Melamed MR, Flehinger BJ, Zaman MB, et al. Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New-York. Chest 1984; 86:44-53.
65. Fontana RS, Sanderson DR, Taylor WF, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic study. Am Rev Resp Disease 1984; 130:561-565.
66. Frost JK, Ball WC Jr, Levin ML, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study. Am Rev Respir Dis 1984; 130:549-554.
67. Fontana RS, Sanderson DR, Woolner LB, et al. Screening for lung cancer: a critique of the Mayo lung project. Cancer 1991; 67:1155-1164.
68. Fontana RS, Sanderson DR, Woolner LB, et al. The Mayo Lung Project for early detection and localization of bronchogenic carcinoma: a status report. Chest 1975; 67:511-522.
69. Taylor WF, Fontana RS. Biometric design of the Mayo lung project for early detection and localization of bronchogenic carcinoma. Cancer 1972; 30:1344-1347.
70. Wolpaw DR. Early detection in lung cancer. Case finding and screening. Med Clin North Am 1985; 80:63-82.
71. Marcus PM, Porok PC. Reanalysis of the Mayo lung project data: the impact of confounding and effect modification. J Med Screen 1999; 6:47-49.
72. Nawa T, Nakagawa T, Kusano S, et al. Lung cancer screening using low-dose spiral CT: results of a baseline and 1-year follow-up studies. Chest 2002; 122:15-20.
73. Sohue T, Moriyama N, Kaneko M, et al. Screening for lung cancer with low dose helical computed tomography: anti-lung cancer association project. J Clin Oncol 2002; 20:911-920.
74. Diederich S, Wormanns D, Semik M, et al. Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers. Radiology 2002; 222:773-781.
75. Swensen SJ, Jett JR, Sloan JA, et al. Lung cancer screening with CT: Mayo Clinic experience. Radiology 2003; 226:756-761.
76. Mahadevia PJ, Fleisher LA, Eng J, et al. Lung cancer screening with helical computed tomography in older adult smokers; a decision and cost-effectiveness analysis. JAMA 2003; 289:313-322.
77. (NLST) NCI: National Institutes of Health. Available at: clinicaltrials.gov/ct/gui/show/ NCT00047385;jsessionid=20DAB829F5CA123FB490104A003ABA?order=1, 2002; Accessed May 2, 2005.
78. Gohagan JK, Prorok PC, Hayes RB, et al. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 2000; 21:251S-272S.
79. Prorok PC, Andriole GL, Bresalier RS, et al. Design of The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000; 21(suppl):273S-309S.